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Aim. Height is an important determinant of augmentation index (AI) that anticipates cardiovascular prognosis. There is a scanty
of the data whether short height predicts survival in patients with end-stage renal diseases, a high risk population. Methods.F i f t y
two hypertensive patients with type 2 diabetic nephropathy receiving hemodialysis and 52 patients with nondiabetic nephropathy
were enrolled. In addition to AI estimated with radial artery tonometry, classical cardiovascular risk factors were considered.
Patients were followed for 2 years to assess cardiovascular prognosis. Results. Cox hazards regression revealed that both smoking
and shortness in height independently contributed to total mortality and indicated that smoking as well as the presence of left
ventricular hypertrophy predicted cardiovascular mortality. Our ﬁndings implicated that high AI, the presence of diabetes, and
low high-density lipoprotein cholesterol were signiﬁcant contributors to cardiovascular events. Conclusions. Our ﬁndings provide
new evidence that shortness in height independently contributes to total mortality in hemodialysis patients.
1.Introduction
Recent technical advance enables noninvasive screening of
arterial stiﬀness, and an increase in arterial stiﬀness is a
characterofatherosclerosis[1–9].Pulsewavevelocity(PWV)
and augmentation index (AI) are good examples. Both
PWV and AI predict cardiovascular survival in patients with
hypertension or renal insuﬃciency [4–9]. Recently, ASCOT-
CAFE study has clearly demonstrated that an elevated
augmentation index (AI) is an important cardiovascular risk
in hypertensive patients [9]. Although PWV could predict
cardiovascular mortality in diabetes [5], there is scanty of
data on AI. Furthermore, available data in diabetes failed
to provide a consistent pattern. On the one hand, Lacy et
al. demonstrated that diabetes showed an elevated PWV
but a normal AI [10]. On the other hand, Westerbacka
et al. reported that AI was associated with carotid intima-
media thickness in diabetes [11]. AI is a dynamic index of
arterial stiﬀness, reﬂecting not only elastic but also muscular
artery stiﬀness [12, 13]. The stiﬀness of muscular artery
is modulated by vasoactive agents including nitric oxide,
angiotensin II, and autonomic nerve activity. Collectively,
variations in these factors may elicit changes in AI. Indeed,
we have demonstrated that AI in diabetes shows abnormal
regulations following acute postural changes [14].
There is a debate on the relationship between height and
cardiovascular disease. A recent meta-analysis demonstrated
that short statue is associated with coronary heart disease
[15]. In contrast, studies from South Korea indicated that
height inversely related to mortality in both men and women
without an association with coronary heart disease [16, 17].
Lee et al. reported an opposing relation of height with death
from cardiovascular diseases and cancers among people
in Asia-Paciﬁc area [18]. Various mechanisms underlying
this relation are proposed such as poor nutrition during
childhood, increased LDL cholesterol, genetic liability, high
pulse pressure, and systolic blood pressure in adults with
short height [15–21]. Indeed, systolic blood pressure is
suited to assess cardiovascular risk in Japanese [22]. Of
interest, height is inversely related to AI, and high AI is2 Cardiology Research and Practice
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Figure 1: Kaplan-Meier analysis on whole hemodialysis patients
showed that nonsmokers survived better than smokers. Log-rank
test denoted that there was a signiﬁcant diﬀerence in mortality
between smoker and nonsmoker.
a cardiovascular risk [9]. Cardiovascular diseases are major
causes of death in hemodialysis patients [23]. The present
study was performed to assess whether short height predicts
mortality in renal patients.
Diabetesaswellashypertensioniswell-knowncardiovas-
cular risk factors. Recent data indicated that cardiovascular
events occurred three times more frequently in patients with
chronic kidney diseases [24]. Diabetes is now a primary
disease, which requires renal replacement therapy [5, 25].
Moreover, although dialysis therapy saves their lives, it may
also burden additional cardiovascular risks to them. In
the present study, the relationship between cardiovascular
risk factors including AI and cardiovascular prognosis was
examined in hypertensive patients with diabetic and non-
diabetic nephropathy receiving regular dialysis therapy. Our
data provide the evidence that left ventricular hypertrophy
(LVH) predicts cardiovascular events in diabetic patients
undergoing hemodialysis. In addition, the present results
indicate that nondiabetic patients with higher AI suﬀered
frommorecardiovascularevents.Ourﬁndingsimplicatethat
smoking and LVH predict cardiovascular death, and further
suggest that in addition to smoking, short statue is a risk for
mortality in hemodialysis patients.
2. Methods
Patients who visited our oﬃces to perform chronic he-
modialysis were listed for the study when they accept
the informed consent. The following patients were not
enrolled:patientswithmyocardialinfarctionorstrokewithin
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Figure 2: Kaplan-Meier analysis on whole hemodialysis patients
showed that those without left ventricular hypertrophy (LVH)
suﬀered cardiovascular death less than those with LVH. Log-rank
test denoted that there was a signiﬁcant diﬀerence in cardiovascular
mortality between patients with LVH and those without.
6months, patients with unstable angina pectoris, patients
with persistent arrhythmia, patients with heart failure or
left ventricular ejection fraction of 40% or less, patients
with peripheral artery disease (stage 3-4), and patients with
overt secondary hyperparathyroidism [26]. Patient entry
was started in 2003, and 52 type II diabetic patients with
nephropathy entered the study. Age- and sex-matched 52
nondiabetic hemodialysis patients were enrolled as controls
to perform case-control study. All 104 patients received
hemodialysis therapy for 4 hours, 3 days a week. Dry
weight was carefully determined for an individual patient
to achieve edema-free state in references to blood pres-
sure and cardiac thorax ratio. In selected patients, end-
diastolic left ventricular diameter, inferior vena cava diam-
eter, and plasma level of atrial natriuretic peptide were also
assessed.
Radial AI was assessed using automated tonome-
try (HEM9010-AI, Omron Healthcare). This device was
designed to automatically record pulse waves using series of
tonometric sensors faced on radial artery. AI was determined
by dividing reﬂection pressure by ejection pressure with
variations of 4.4% [27]. This device also measures blood
pressure using an oscillometric method. Two measurements
were performed with the patient in the sitting position
for 5 and 10 minutes, respectively, and the average of the
2 values was taken for the purpose eﬃcacy analysis. This
device was able to estimate central blood pressure expressed
as SBP2 [28]. Electrocardiogram and blood samples were
taken from all patients at the time of entry. The following
criteria were used to diagnose LVH; Sokolow-Lyon voltageCardiology Research and Practice 3
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Figure 3: Kaplan-Meier analysis on whole hemodialysis patients
showed that those without diabetes experienced cardiovascular
events less frequently than those with diabetes. Log-rank test
depicted that there was a signiﬁcant diﬀerence in cardiovascular
events between patients with diabetes and those without.
amplitude of (SV1 + RV5 or RV6) > 3.5 m V ,aC o r n e l l
voltage of (SV3 + RaVL) > 2.8mV, or a Cornell product of
[(SV3 + RaVL) × QRS duration] > 244mV. Left ventricular
strain was deﬁned as a down-sloping ST-segment depression
> 0.1mV with T-wave ﬂattening or inversion in leads V4
to V5 [29]. Blood sample was drawn after overnight fast for
accuracy.
The patients were followed for 2 years or until car-
diovascular events occurred. Cardiovascular events included
coronaryarterydisease,stroke,andperipheralarterydisease.
Heart failure was excluded because pulmonary edema only
due to ﬂuid retention is common in this patient popula-
tion [30]. Thus, the following patients were considered to
possesscardiovascularevents:patientswithacutemyocardial
infarction, those with angina pectoris being treated by either
bypass surgery or balloon angioplasty, patients with brain
infarction or bleeding, and patients with peripheral artery
disease who received limb amputation, balloon angioplasty,
or bypass surgery.
Cox hazard analysis with Wald modiﬁcation was per-
formed to assess cardiovascular risk. In addition to AI, the
presence or absence of LVH and diabetes, classical Flaming-
ham risk factors including age, sex, height, weight, mean
blood pressure (MBP), pulse rate (PR), total cholesterol
(TC), high-density lipoprotein cholesterol (HDL-C), triglyc-
eride (TG), and current smoking were used as independent
variables. Nonclassical risk factors such as serum albumin,
hemoglobin (Hb), hemodialysis duration, and KT/V were
also considered as independent variables. AI showed signif-
icant relationship with SBP and SBP2 (P<. 01). Since we
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Figure 4: Kaplan-Meier analysis on nondiabetic hemodialysis
patients showed that those with higher AI failed to live cardiovas-
cular event-free lives similar to those with the lower AI. Log-rank
test denoted that there was a signiﬁcant diﬀerence in cardiovascular
events between two subgroups.
used AI, an index of arterial stiﬀness, as an independent
variable, MBP was selected as an independent variable of
blood pressure component to decrease multi-co-linearity
[31]. Kaplan-Meier analysis was performed to assess a
contributor to cardiovascular events. Cox hazard model was
also applied to consider cardiovascular risk in diabetic and
nondiabetic groups, respectively. Age, sex, height, weight,
MBP, PR, TC, HDL-C, TG, AI, the presence or absence of
LVH and smoking were used as independent variables in
subgroupanalysis.ThemedianofAIandHDL-Cwasusedto
divide patients into two groups. Stepwise regression analysis
wasusedtoassesswhichpatientbackgroundsdeterminedAI.
Receiver operation characteristic (ROC) analysis was used to
assess cut-oﬀ value of AI to predict cardiovascular events.
Fisher’s exact test and Student t-test were used to compare
patient background between groups. P<. 05 was considered
signiﬁcant.
3. Results
Table 1 summarized patient background for two groups. In
each group, there were 11 females and age was averaged
59 y/o at the time of study entry. Height, weight, MBP,
PR, AI, TC, HDL-C, and the prevalence of smokers were
similar between nondiabetic and diabetic groups. Twenty
diabetic patients were on insulin therapy, and 10 took
voglibose. The other 22 diabetes were diet therapy alone.
Averaged HbA1c was 6.1 ± 0.3% in diabetes. LVH was
more frequently observed in diabetes than nondiabetics,
and TG was higher in diabetes. Although serum albumin4 Cardiology Research and Practice
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Figure 5: ROC curve for nondiabetic patients showed that AI
of 87 was able to be used as a cutoﬀ value to (arrow) predict
cardiovascular events.
(3.8 ± 0.3v e r s u s3 .8 ± 0.2g/dl), Hb (10.0 ± 0.5v e r s u s
9.9 ±0.6g/dl), and dialysis eﬃciency (KT/V; 1.1 ±0.1v e r s u s
1.1 ± 0.1) were similar between 2 groups, the duration of
hemodialysisindiabeteswasshorterthanthatofnondiabetic
patients. Most patients took antihypertensives. Either an
angiotensin converting enzyme inhibitor or an angiotensin
receptor blocker was prescribed for 87% of diabetic patients
and 77% of nondiabetic patients. Statins were prescribed for
58% of diabetic patients and 54% of nondiabetic patients.
No patients took ﬁbrates, because Ministry of Health, Labor
and Welfare Japan prohibited their application for patients
with renal insuﬃciency. Erythropoietin was administered
to treat renal anemia and titrated to maintain hemoglobin
around 10g/dl. The doses of erythropoietin were similar
between diabetic (3800 ± 435IU/week) and nondiabetic
patients (3950 ±383IU/week).
Three patients died during 2 years in the nondiabetic
group. The causes of death were stroke (2 cases) and gastric
cancer. Eight diabetic patients died during observation
periods. Three diabetic patients were dead from myocardial
infarction, two from stroke, and one from peripheral artery
diseases. The other two patients died from renal cell carci-
noma and pneumonia. Thus, only 5% of patients were dead
for a year in the present study. As with previous reports, our
results support a signiﬁcant small death rate of hemodialysis
patients in Japan, compared to US or Europe [32].
Cox hazard analysis demonstrated that both smoking
(P<. 05) and shortness in height (P<. 05) considerably
contributed to total mortality (Table 2). Figure 1 depicted
Kaplan-Meier analysis indicating a signiﬁcant diﬀerence in
survival curves between smokers and nonsmokers (P<. 05).
Cox hazard model selected both smoking (P<. 05) and
LVH (P<. 05) as signiﬁcant contributors to cardiovascular
Table 1: Demographic feature of participating patients.
Non-DM DM
Age (y/o) 59 ±13 59 ±12
Sex (M/F) 41/11 41/11
height (cm) 164 ±9 163 ±8
Weight (kg) 60 ±10 60 ±11
SBP (mmHg) 143 ±19 146 ±20
DBP (mmHg) 69 ±13 67 ±16
SBP2 (mmHg) 127 ±16 129 ±18
MBP (mmHg) 94 ±12 94 ±13
PR (bpm) 78 ±18 79 ±10
TC (mg/dl) 157 ±42 158 ±36
HDL-C (mg/dl) 40 ±15 36 ±11
TG (mg/dl) 115 ±45 134 ±52
∗
Smoking (%) 19 25
AI 78 ±21 79 ±20
LVH (%) 15 46
∗
HD duration (yrs) 12.4 ±1.09 .6 ± 0.8
∗
DM, HD, PR, TC, HDL-C, TG, AI, LVH, SBP, SBP2, DBP, and MBP
depicted diabetes mellitus, hemodialysis, pulse rate, total cholesterol,
high density lipoprotein cholesterol, triglyceride, augmentation index, left
ventricularhypertrophy,systolic,central,diastolicandmeanbloodpressure,
respectively. ∗indicates signiﬁcance between groups.
Table 2: Cox hazard stepwise regression analysis for all mortality
(whole patients). χ2 = 8.54, df = 2, P = .014.
Variable β SE Wald Probability
Smoking 1.65 0.65 6.35 0.012
Height −0.082 0.038 4.80 0.028
SE; standard error.
Table 3: Cox hazard stepwise regression analysis for cardiovascular
mortality (whole patients). χ2 = 10.22, df = 2, P = .006.
Variable β SE Wald Probability
Smoking 1.858 0.731 6.45 0.011
LVH 1.372 0.713 3.52 0.041
SE and LVH indicate standard error and left ventricular hypertrophy.
mortality (Table 3). As shown in Figure 2, patients with
LVH survived less than those without (P<. 05). As shown
in Table 4, however, Cox hazard analysis showed that the
presence of diabetes (P<. 05), high AI (P<. 05), and low
HDL-C(P<. 05)contributedtocardiovasculareventsinthis
study. Figure 3 depicted that diabetic patients suﬀered more
cardiovascular events than nondiabetic patients (P<. 05).
Subgroup analysis was also performed. In nondiabetic
patients, Cox hazard model failed to ﬁnd signiﬁcant con-
tributors to total and cardiovascular mortality. However, it
selected high AI as a contributor to cardiovascular events
(Table 5). Figure 4 exhibits Kaplan Meier analysis which
showed that patients with low AI enjoy cardiovascular event-
free lives longer than those with high AI. As illustrated in
Figure 5, ROC analysis has shown that the cutoﬀ value ofCardiology Research and Practice 5
Table 4: Cox hazard stepwise regression analysis for cardiovascular
events (whole patients). χ2 = 23.3, df = 3, P = .0001.
Variable β SE Wald Probability
AI 0.026 0.009 8.499 0.004
HDL-C −0.045 0.018 6.208 0.013
DM 1.155 0.394 8.593 0.003
SE, AI, HDL-C, and DM depicted standard error, augmentation index, high
density lipoprotein cholesterol, and diabetes mellitus.
Table 5: Cox hazard stepwise regression analysis for cardiovascular
events (nondiabetic patients). χ2 = 11.42, df = 1, P = .001.
Variable β SE Wald Probability
AI 0.064 0.021 9.090 0.003
SE and AI described standard error and augmentation index.
Table 6: Cox hazard stepwise regression analysis for cardiovascular
events (diabetic patients). χ2 = 10.07, df = 2, P = .007.
Variable β SE Wald Probability
HDL-C −0.047 0.021 4.819 0.028
LVH 0.987 0.425 5.405 0.020
SE, HDL-C, and LVH denoted standard error, high density lipoprotein
cholesterol, and left ventricular hypertrophy.
Table 7: Stepwise regression analysis for AI (nondiabetic patients).
R2 = 0.428, RMSE 16.52, F = 18.33, P<. 001.
Variable β SE tP
Age 0.644 0.198 3.249 0.002
Height −0.926 0.306 −3.029 0.004
AI and SE represented augmentation index and standard error.
Table 8: Stepwise regression analysis for AI (diabetic patients).
R2 = 0.303, RMSE 16.58, F = 10.65, P<. 001.
Variable β SE tP
MBP 0.404 0.178 2.268 0.028
Height −1.140 0.289 −3.940 0.001
AI, SE, and MBP indicated augmentation index, standard error, and mean
blood pressure.
87 for AI predicts the occurrence of cardiovascular events
in nondiabetic hemodialysis patients with sensitivity and
speciﬁcity of 67% and 74%, respectively. In diabetic patients,
Cox hazard model failed to ﬁnd signiﬁcant contributors
to total and cardiovascular mortality as the case with
nondiabeticpatients.However,Coxhazardanalysischosethe
presence of LVH (P<. 05) and low HDL-C (P<. 05) as
the predictors of cardiovascular events (Table 6). Figure 6
demonstrated that hemodialysis patients with the lower
HDL-C failed to live cardiovascular event-free lives similar
to those with the higher HDL-C. Stepwise regression analysis
on patient backgrounds in each group described that age and
height signiﬁcantly contributed to AI in nondiabetic group
(Table 7) and showed that MBP and height determined AI in
diabetic group (Table 8).
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Figure 6: Kaplan-Meier analysis on diabetic hemodialysis patients
showed that patients with higher HDL-C AI enjoy cardiovascular
event-free lives longer than those with lower HDL-C. Log-rank test
denoted that there was a signiﬁcant diﬀerence in cardiovascular
events between the two subgroups.
4. Discussion
Cardiovascular diseases are a major cause of death in
hemodialysis patients [23]. Early detection of cardiovascular
diseases and prevention of cardiovascular events appear
important also in hemodialysis patients. We have previously
reported that cardio-ankle vascular index, another index
of arterial stiﬀness, is useful for this purpose, because it
provides the cutoﬀ value of 7.55 to predict the presence
of cardiovascular diseases in hemodialysis patients [30].
Consistent with Covic et al. [33], our study suggests that
the measurement of AI is also useful to screen the pres-
ence of cardiovascular diseases even if asymptomatic. ROC
analysis showed that the cutoﬀ value of 87 for AI predicted
the occurrence of cardiovascular events in nondiabetic
hemodialysis patients. Together, the presentﬁndings indicate
that nondiabetic hemodialysis patients possessing AI over 87
should receive further medical examinations for the presence
of cardiovascular diseases and implicate a critical role of
central blood pressure in the development of cardiovascular
events in hemodialysis patients.
Our results constitute a novel ﬁnding that the shortage
in height contributed to total death in the present study.
Shortness in height would reduce the time required for
reﬂection wave to reach ascending aorta, thereby increasing
AI [13]. Indeed, stepwise regression analyses demonstrated
that the determinant of AI consisted of the height in
both diabetic and nondiabetic groups. However, Kaplan-
Meier analysis failed to attain statistical signiﬁcance when a
comparison was made to mortality between tall and short
patients.Althoughprecisereasonsforthediscrepancyarenot6 Cardiology Research and Practice
readily apparent from the present study, several confounding
factors could be involved. Smokers prevailed in the tall
patients (16 smokers) more than short ones (7 smokers).
ASCOT-CAF´ EstudydemonstratedtheadvantageoflowerAI
for better cardiovascular outcomes in hypertensive patients
[9]. As discussed (bide infra), AI measured in the sitting
position, however, may be inappropriately low in diabetic
group possibly due to the presence of neuropathy [14].
Taken together, these observations could account for that the
shortness of height, an important determinant of AI, but
not AI itself, was picked up as a risk factor of mortality.
It is tempting to speculate that patients with short height
are exposed to high AI and high central blood pressure,
even if brachial blood pressure is controlled similarly to tall
patients. Indeed, Asians who suﬀer more cerebrovascular
attacks than coronary heart disease are generally shorter
than Caucasians [18]. The diﬀerence in body size as well as
racial background may underlie high prevalence of stroke in
Asia. Alternatively, the treatment goal of blood pressure for
hypertensive patients should be individualized and adjusted
by taking the inﬂuence of height on central blood pressure
into consideration [34]. Taken together, these observations
raise the possibility that blood pressure should be more
carefully controlled for patients with short height such as
women [35].
Several factors such as age, LVH, and arterial stiﬀness
have been reported to predict cardiovascular prognosis.It
seems controversial that AI constitutes a good predictor of
cardiovascularcomplicationsindiabetes[10].Indeed,AIwas
selectedasanimportantcontributortocardiovascularevents
fornondiabeticbutnotdiabeticpatientsinthepresentstudy.
Thepresentresultssupportarecentinvestigationimplicating
that pulse pressure predicted cardiovascular survival in
nondiabetic, but not diabetic hemodialysis patients [36]. In
this study, however, LVH was selected as one of contributors
to cardiovascular events in diabetes. Our previous data
demonstrated that AI positively correlated to left ventric-
ular mass Index in patients with nondiabetic CKD [27].
Our recent data demonstrated that patients with diabetic
nephropathymanifestedgreaterdecreasesinAI,brachialand
centralbloodpressureswhentheirposturesalterfromsupine
to sitting position than those with nondiabetic CKD [14].
The patient with diabetic nephropathy commonly suﬀers
neuropathy as well [37]. Diabetic neuropathy could fade
appropriate vasoconstriction following to postural changes,
resulting in a large decrease in reﬂection wave. Alternatively,
sleep may markedly increase central blood pressure in
diabetes with neuropathy and facilitate the development of
LVH. Collectively, blood pressure control at night in lying
position would be important to prevent LVH, cardiovascular
events, and death, especially in diabetes.
Atherosclerotic cardiovascular diseases constitute a
major cause of death in diabetic patients [38]. Frequently,
type II diabetes has already manifested atherosclerotic
vascular lesions at the time of diagnosis, and the pres-
ence of atherosclerosis makes their survival shorter and
may increase total medical cost. Thus, the prevention
and detection of atherosclerosis and cardiovascular com-
plications in diabetes should be of clinical signiﬁcance.
In addition to glycemic control, lipid-lowering drugs, and
renin-angiotensin inhibitors appear as promising therapeu-
tic tools to retard the development of atherosclerosis in
diabetes [39, 40]. In consistent, this study demonstrated
that diabetes was a signiﬁcant contributor to cardiovascular
events. The usage of RAS inhibitors and statins was similar
between diabetic and nondiabetic group, suggesting that the
diﬀerences in medication between groups might have played
a small role [39–41]. Our recent data indicated that oxidized
LDL was higher in diabetic patients than those without
diabetes [26]. Thus, the present results are compatible
with recent investigations which revealed that oxidative
stress underlies diabetic nephropathy [42], and suggest that
oxidative stress is also involved in the pathogenesis of
cardiovascular diseases in diabetes.
Chronic kidney disease (CKD) is characterized by
oxidative stress [43, 44]. In the case of hemodialysis, the
contact of blood cells with dialyzer membrane may generate
more oxidative stress to the patient. We have previously
demonstrated that oxidized LDL was sky high in hemodial-
ysis patients [45]. Our recent data suggest that oxidative
stress induces insulin resistance, which is an important
cardiovascular risk factor in hemodialysis patients [26]. It
is easy to expect that the superimposition of exogenous
oxidative stress on endogenous one would increase cardio-
vascular risk. Oxidative stress also causes the damage of
DNA and histones, possibly underlying the pathogenesis of
cancer [46]. Consequently, the present results that smoking
stronglycontributedtototalandcardiovascularmortalityare
consistent with the above, and suggest that the prohibition of
smoking is encouraged especially for CKD patients.
HDL-C plays a pivotal role in lipid metabolism by up-
taking redundant cholesterol and carrying it back to liver
for degradation. Recent investigations reveal that HDL-
C possesses strong antioxidant activity [47, 48]. In the
present study, low HDL-C was selected as the contributor to
cardiovascular events when diabetic as well as whole patients
were examined. Our previous data indicated that higher
oxidized LDL resulted in lower ankle-brachial pressure
index in hemodialysis patients [45], and that hemodialysis
patients with low ABI exhibit a strong tendency to develop
cardiovascular events [26]. Our data seem compatible with
those by Nishizawa et al. that non-HDL-C such as interme-
diate density lipoprotein cholesterol is highly atherogenic in
hemodialysis patients [49] and suggest that in patients with
CKD, the eﬀorts to maintain HDL-C level such as aerobic
exercise are more important for vascular health than those
without renal dysfunction.
This study shares several limitations. Although further
larger scale study should be required before drawing con-
clusion, the present data suggest that the values of AI in
sitting position as a predictor of cardiovascular prognosis
in hypertensive patients with diabetic nephropathy might be
less than our expectation. Prospective studies that utilize AI
measured in lying position should be required to examine
AI as a predictor of cardiovascular prognosis in diabetes.
Second, the usage of echocardiographic LVH as a risk factor
might give diﬀering results because electrocardiographic
LVH does not always reﬂect echocardiographic LVH [29].Cardiology Research and Practice 7
Thirdly, although TG was higher in diabetes, HDL-C was
similar between the 2 groups in this study. However, TG
did not contribute to either cardiovascular death or events.
While the reasons for this discrepancy are not readily clear,
we should note that TG levels were not so high in diabetes
and that blood glucose was fairly controlled, presumably
accounting for this. Fourthly, nonclassical risk factors such
as albumin and anemia were not selected as a signiﬁcant
contributor to mortality or cardiovascular events. We should
note that the patients enrolled in the present study were
relatively young and shared well nutrition. Finally, oxidative
stress and central hypertension may cause crosstalk to each
other. Oxidative stress should increase central blood pressure
by attenuating the actions of nitric oxide on artery, and high
central blood pressure could induce oxidative stress de novo.
In conclusion, the present observations provide new
evidence that shortness in height independently contributes
to mortality in hemodialysis patients.
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